~~<i id='FFB957DBB6'><strike id='FFB957DBB6'><tt id='FFB957DBB6'><pre id='FFB957DBB6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：hotspot 2025-09-06 04:41:35 - browse：8

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： A controversial new treatment promises to make little people taller

Wikipedia

hotspot

explore

knowledge

KristofferTripplaar/SipaUSA/APAlnylamPharmaceuticalssaidThursdaythatsalesofitstreatmentsforraredisea

WSS

Belarusian journalist sentenced to 4 years in prison as crackdown continues

How I helped Pfizer think through the ethics of Viagra

The strange history of BMI, the body mass index

Medical experts exlpore how to eliminate bias in clinical algorithms

Brazil's Jair Bolsonaro is barred from running for office until 2030

How I helped Pfizer think through the ethics of Viagra

focus

fashion

Wikipedia

At least 13 dead in Texas as scorching temps continue

The simple reason for the increase in autism diagnosis

Moonlake's readout produced a cash windfall. Risks remain

Heart disease in astronauts blamed on cosmic radiation

Duchenne breakthrough therapy leaves behind pioneering families

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Guidelines to prevent youth baseball injuries need more muscle

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Heart attack and stroke risk calculators need revising

Eating disorder hotline's move to chatbot carried cost for volunteers

Wikipedia

Biotech startup Celsius cuts 75% of staff ahead of first trial start

The strange history of BMI, the body mass index

Synthetic human embryos? Researchers say term is overblown

The a glaring gap in research on serious mental illness and primary care

Study links childhood stress with decline in older age

Alnylam reports growth in sales of rare disease treatments

hotspot

explore

knowledge

knowledge